3 years ago

Actimed Therapeutics Closes £5M Seed Funding for Cancer Cachexia Treatment

  • Actimed Therapeutics, a UK-based clinical stage pharmaceutical company, closed its second and final £5M tranche of Seed financing

  • This brings the total seed funding raised by Actimed to approximately £10M

  • The company intends to use the funds to support the development of its portfolio, including preparation for the Phase 2b/3 programme for its lead asset, S-pindolol benzoate, being developed for the treatment of cancer cachexia

  • Actimed Therapeutics is focused on bringing innovation to the treatment of muscle wasting disorders.

      • ProblemHealthcare

      "Cancer cachexia, a wasting disease associated with cancer and other serious chronic illnesses, leads to significant morbidity and mortality for patients."

      Solution

      "Actimed Therapeutics is developing S-pindolol benzoate (ACM-001.1) to target multiple pathways that drive cachexia and has promising Phase 2a clinical data. They are now preparing for Phase 2b/3 clinical studies in Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC)."

      Covered on